Clinical Research
Filter News
Found 147,653 articles
-
Health economics and outcomes research (HEOR) is a critical but sometimes overlooked part of drug development. Decentralized trials now make it easy.
-
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
3/27/2024
Innovent Biologics, Inc. announces that the first participant has been successfully dosed with IBI310 in combination with sintilimab in a randomized, controlled, multicenter Phase 3 clinical trial, for resectable MSI-H/dMMR[1] colon cancer neoadjuvant therapy.
-
Ludwig Enterprises Inc (OTC:LUDG) Funds Incurable Brain Cancer Study
3/27/2024
Ludwig Enterprises, Inc is pleased to announce that its subsidiary Exousia AI is funding a preclinical study on Glioblastoma, an incurable brain cancer.
-
Linear Health Sciences Publishes Whitepaper Examining IV Dislodgement
3/27/2024
Linear Health Sciences announced the publication of a new whitepaper on accidental dislodgement of IV catheter lines.
-
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
3/27/2024
argenx SE announced its plan to continue the development of efgartigimod to Phase 3 in adults with primary Sjogren’s disease, following the analysis of topline data from the Phase 2 RHO study.
-
Chemical Insights Research Institute Shares its Latest Research Findings on PFAS Associated with Consumer and Commercial Textiles
3/27/2024
Chemical Insights Research Institute of UL Research Institutes has released its first report on a multi-phase research study of per- and polyfluoroalkyl substances, commonly referred to as “forever chemicals,” associated with consumer and commercial textiles.
-
Cantargia Reports Progress Towards Start of DOD-Sponsored Clinical Trial of Nadunolimab in Leukemia
3/27/2024
Cantargia Cantargia reported on the progress in the upcoming phase Ib/IIa clinical trial investigating nadunolimab in up to 40 patients with acute myeloid leukemia or myelodysplastic syndrome.
-
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
3/27/2024
Algernon Pharmaceuticals Inc. is pleased to announce that it has closed on its agreement with Seyltx Inc., a privately owned U.S. based drug development company, for the acquisition of Algernon’s NP-120 research program for the purchase price of USD $2M cash and a 20% common share equity position in Seyltx.
-
Biosenta Announces Successful Launch of Bench Scale Production Plant and Exceeding Expectations of Tri-Filler(TM) Particle Encapsulation Technology
3/27/2024
Toronto, Ontario and Calgary, Alberta--(Newsfile Corp. - March 27, 2024) - Biosenta Inc. (CSE: ZRO) ("Biosenta" or the "Company") is pleased to announce a significant milestone in its technological and operational advancements with the successful construction and operation of a bench scale production plant.
-
Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines
3/26/2024
Telomir Pharmaceuticals, Inc. announced that Telomir and global animal health research company Argenta have agreed to begin a three to six-months study on the efficacy of Telomir-1 as a treatment for osteoarthritis and other diseases of aging in canines.
-
A Revolutionary Breakthrough in Biomedical Testing: AmeboGenesis Introduces Sustainable Amebocyte Production for LAL Testing to Detect Bacterial Contamination
3/26/2024
AmeboGenesis™ has achieved a significant milestone with the introduction of a sustainable Amebocyte production process.
-
Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
3/26/2024
Actinium Pharmaceuticals, Inc. announced that the University of Texas Southwestern Medical Center will lead a clinical trial studying Actinium's Iomab-ACT, a targeted radiotherapy conditioning agent prior to patients receiving an FDA approved commercial CAR T-cell therapy.
-
Bridge Biotherapeutics Announces a Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology
3/26/2024
Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr. Raul Torres's Lab at the University of Colorado School of Medicine.
-
Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure
3/26/2024
Tectonic Therapeutic, Inc., a privately-held biotechnology company developing GPCR -targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, announced the initiation of enrollment in the Phase 1B study for TX45, an investigational long-acting relaxin-Fc fusion molecule.
-
Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease
3/26/2024
A blood test that analyzes levels of amyloid proteins by highly sensitive mass spectrometry could help physicians establish that Alzheimer's disease is likely not the cause of patients' mild cognitive impairment, finds a new study published in Frontiers in Neurology by researchers from Quest Diagnostics, the University of Florida and Mount Sinai Medical Center in Miami Beach.
-
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
3/26/2024
Moderna, Inc. announced that mRNA-1283, the Company's next-generation COVID-19 vaccine, has successfully met the primary endpoints of its Phase 3 clinical trial, demonstrating a higher immune response against SARS-CoV-2 when compared to mRNA-1273.222, Moderna's licensed COVID-19 vaccine.
-
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
3/26/2024
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, provided an update on its Phase 2a proof of concept study evaluating PRAX-628 in epilepsy patients with PPR.
-
Peer-Reviewed Scientific Publication Proposes Unifying Single Toxin Theory of Brain Neurodegeneration that Identifies New Drug Targets and Treatments for Alzheimer’s Disease and Other Neurodegenerative Disorders
3/26/2024
Alzheon, Inc. announced the publication of a peer-reviewed research paper, “The Single Toxin Origin of Alzheimer’s Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention”.
-
Defence's Successful Results on Its AccuTOX Anti-Cancer ARM Vaccine Creates a Potent Second-Generation Anti-Cancer ARM-002 Vaccine
3/26/2024
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biotechnology company developing novel
-
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
3/26/2024
Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI) today announced the online publication of the manuscript "Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and nonhuman primate models" in Nature Communications (“Springer-Nature"), an international journal publishing peer-reviewed research in all fields of science and technology.